Notably, ERK5 is the only known cellular target of MEK5, and overexpression of MEK5 is associated with aggressive prostate cancer [85], cellular hypertrophy in cardiomyocytes [86], and impaired angiogenesis [87]. Here, MAP2K5 is linked to prostate carcinoma.